News & Blog

Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia

Meet The Community: Zoë Graef

Meet The Community: Osama Alawik

Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia

Meet The Community: Brett Davis

Meet The Community: Matthew Jordan Penman

Meet The Community: María Luisa Ledesma Cano

Meet The Community: Elsaid Younes

Meet The Community: Julia Mancebo López

Meet The Community: Valbona Ferati

Meet The Community: Frances Clair

Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics